

**\*NOTE: NURSE MUST INITIAL EACH INDIVIDUAL ORDER**

RN	HUS	Fill in blanks and boxes to initiate order(s).		
		Date/Time:	Allergies:	Height (centimeters):
		Weight:	Ideal body Weight (IBW):	Adjusted body weight: (= IBW + 0.4 [Actual -IBW])
		<b>DIAGNOSIS:</b> Check appropriate box <input type="checkbox"/> Autoimmune Blistering Skin Diseases <input type="checkbox"/> Bone Marrow Transplant <input type="checkbox"/> Chronic Inflammatory Demyelinating Polyneuropathy <input type="checkbox"/> Chronic Lymphocytic Leukemia <input type="checkbox"/> Clostridium difficile (severe, recurrent)* <input type="checkbox"/> Dermatomyositis/ Polymyositis <input type="checkbox"/> Desensitization- allosensitized kidney and intestine transplant candidates <input type="checkbox"/> Desensitization- cardiac/ lung transplantation <input type="checkbox"/> Fetomaternal Alloimmune Thrombocytopenia	<input type="checkbox"/> Guillain-Barre Syndrome <input type="checkbox"/> Hemolytic Disease of Fetus/ Newborn <input type="checkbox"/> Idiopathic Thrombocytopenia <input type="checkbox"/> Kawasaki Disease <input type="checkbox"/> Kidney or Intestine transplant- documented acute humoral rejection <input type="checkbox"/> Lambert Easton Myasthenic Syndrome <input type="checkbox"/> Multifocal Motor Neuropathy <input type="checkbox"/> Myasthenia Gravis <input type="checkbox"/> Post-Transfusion Purpura <input type="checkbox"/> Parvovirus B-19 infection associated with pure red cell aplasia	<input type="checkbox"/> Primary Immunodeficiency (specify): _____ <input type="checkbox"/> Rotaviral Enterocolitis* <input type="checkbox"/> Stiff Person Syndrome <input type="checkbox"/> Systemic Lupus Erythematosus* <input type="checkbox"/> Systemic Vasculitic Syndromes <input type="checkbox"/> Toxic Epidermal Necrolysis/ Stevens-Johnson Syndrome* <input type="checkbox"/> Toxic Shock Syndrome* <input type="checkbox"/> Other (requires approval): _____  <b>* Requires specialists' approval</b>
		<b>PREMEDICATION (ADULTS):</b> 30 minutes prior to infusion <input type="checkbox"/> Acetaminophen: 650 mg oral x 1 dose <input type="checkbox"/> Acetaminophen: 650 mg per rectum x 1 dose <input type="checkbox"/> Diphenhydramine: 25 mg oral x 1 dose <input type="checkbox"/> Diphenhydramine: 25 mg IV x 1 dose <input type="checkbox"/> Other: _____	<b>PREMEDICATION (PEDIATRICS):</b> 30 minutes prior to infusion <input type="checkbox"/> Acetaminophen: _____ mg (15 mg/kg, Max: 650mg) oral x 1 dose <input type="checkbox"/> Acetaminophen: _____ mg (15 mg/kg, Max: 650mg) per rectum x 1 dose <input type="checkbox"/> Diphenhydramine: _____ mg (1 mg/kg, Max: 50mg) oral x 1 dose <input type="checkbox"/> Diphenhydramine: _____ mg (1 mg/kg, Max: 50mg) IV x 1 dose <input type="checkbox"/> Other: _____	
		<b>IMMUNE GLOBULIN (IVIG) PRODUCT SELECTION: (check one product)</b> <input type="checkbox"/> Octagam 5%- Preferred product. Non-sucrose containing product. Contraindicated in corn allergy. <input type="checkbox"/> Gammaked 10%- Non-sucrose containing product. Justification for use must be provided in order to dispense: _____		
		<b>DOSE:</b> Orders for IVIG will be automatically dose rounded to the vial size except in neonates. Refer to Table for Recommended Doses. Assure that patient is not volume depleted prior to initiation of IVIG infusion. <input type="checkbox"/> IVIG _____ grams/kg/dose (Example: 0.4 g/kg, 0.5 g/kg, 1g/kg , 2 g/kg ) IV once on _____ (Date of administration) <input type="checkbox"/> IVIG _____ grams/kg/dose IV once every _____ day(s) for _____ doses <input type="checkbox"/> IVIG _____ grams/kg/dose (Example: 0.1 g/kg or 0.15 g/kg) after plasmapheresis IV once on _____ (Date of administration)		
		<b>DOSE CONSIDERATIONS:</b> All patients will be dosed based on IBW except pediatrics, patients whose actual body weight is less than IBW and obese patients greater than 100 kg or BMI greater than 30 kg/m <sup>2</sup> (use adjusted body weight in obese patients).		
		<b>MONITORING:</b> Vital signs: Prior to start of infusion, then every 30 minutes for 1 hour, then every hour for duration of infusion. Anaphylactic response may occur within 30 to 60 minutes of start of infusion. Notify physician for face flushing, chest tightness, chills, fever, dizziness, nausea, vomiting, diaphoresis and hypotension. <b>If any reaction occurs, stop the infusion (do not discard) and contact prescriber.</b>		
		<b>INFUSION CONSIDERATIONS:</b> <ul style="list-style-type: none"> <li>• Patients should be adequately hydrated prior to initiating IVIG therapy.</li> <li>• Consider using slower infusion rates in patients with renal dysfunction, thrombosis or congestive heart failure.</li> <li>• Increase rate only if no adverse reaction occurs. Decreasing rate may help relieve some side effects.</li> <li>• IVIG should be infused separately from all other products and solutions.</li> </ul>		
		<b>OCTAGAM</b>	<b>GAMMAKED</b>	
		Initial rate of 0.01 mL/kg/min (0.6 mL/kg/h) for the first 30 minutes. If well tolerated, may increase rate every 30 minutes to a maximum rate of 0.07 mL/kg/min (4.2 mL/kg/h)	Initial rate of 0.01 mL/kg/min (0.6 mL/kg/h) for the first 30 minutes. If well tolerated, may increase rate every 30 minutes to a maximum rate of 0.08 mL/kg/min (4.8 mL/kg/h)	
		<b>Physician's Signature:</b> _____ <b>Printed Name:</b> _____ <b>I.D. Number:</b> _____ <b>Beeper:</b> _____		

**PHARMACY ORDERS MUST CONTAIN NAME OF MEDICATION -- DOSE -- STRENGTH ROUTE – FREQUENCY**



MIAMI, FLORIDA 33136-1096



PO0010

**Intravenous Immunoglobulin (IVIG) Order Form**

TABLE FOR RECOMMENDED DOSES

FIRST LINE INDICATIONS	
Indication	Recommended Dose
Bone Marrow Transplant	<ul style="list-style-type: none"> <li>500mg/kg/dose every 2 weeks if IgG level less than 500</li> </ul>
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	<ul style="list-style-type: none"> <li>ACUTE: 400 mg/kg/day x 5 days</li> <li>CHRONIC: 500 mg/kg/day x 2 days every 3 weeks or 1 g/kg/dose every 3 weeks</li> </ul>
Desensitization- cardiac/ lung transplant- Panel reactive body greater than 50%	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days every 2 to 4 weeks after final plasmapheresis session</li> <li>Plasmapheresis/IVIG: 150 mg/kg/dose after each session</li> </ul>
Desensitization- allosensitized kidney transplant HLA and intestine transplant	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days every month x 4 months</li> <li>Plasmapheresis: 100 mg/kg/dose after each session</li> </ul>
Desensitization-kidney and intestine transplant, documented acute humoral rejection	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days after final plasmapheresis session</li> <li>Plasmapheresis/IVIG: 100 mg/kg/dose after each session</li> </ul>
Guillain-Barre Syndrome- Severe disease	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Idiopathic Thrombocytopenia (ITP)- Acute ITP with platelet count less than 20,000 / mm <sup>3</sup> or actively bleeding	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Kawasaki Disease- Must be used in combination with aspirin	<ul style="list-style-type: none"> <li>2 g/kg/dose x 1 dose</li> </ul>
Multifocal Motor Neuropathy	<ul style="list-style-type: none"> <li>ACUTE: 400 mg/kg/day x 5 days</li> <li>CHRONIC: 1 g/kg/dose every 2 to 4 weeks or 2 g/kg/dose every 4 to 8 weeks</li> </ul>
Myasthenia Gravis/ Lambert-Easton Myasthenic Syndrome- Severe exacerbation or myasthenic crisis	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Parvovirus B-19 infection- immunocompromised patients with pure red cell aplasia	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Post Transfusion Purpura	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Primary Immunodeficiency (congenital agammaglobulinemia, severe combined immunodeficiency syndromes, common variable immunodeficiency, X-linked immunodeficiency and Wiskott-Aldrich Syndrome)	<ul style="list-style-type: none"> <li>200 to 400 mg/kg/dose every 4 weeks (goal trough of IgG greater than 500 mg/dL)</li> </ul>
SECOND LINE INDICATIONS	
Autoimmune Blistering Skin Diseases- failed standard therapy with steroids or other immunosuppressive therapy	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days every 3 to 4 weeks</li> </ul>
Chronic Lymphocytic Leukemia- hypogammaglobulinemia and severe, recurrent infection	<ul style="list-style-type: none"> <li>400 mg/kg/dose every 3 to 4 weeks</li> </ul>
Dermatomyositis/ Polymyositis- Should be given in combination with steroids or other immunosuppressive therapy	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Fetomaternal Alloimmune Thrombocytopenia- pregnant women with previous history or existing platelet antibodies	<ul style="list-style-type: none"> <li>1 g/kg/dose every week</li> </ul>
Hemolytic Disease of Fetus/Newborn- total serum bilirubin (TSB) is rising despite phototherapy or TSB is within 2 to 3 mg/dL of the exchange level	<ul style="list-style-type: none"> <li>500 mg/kg/dose x 1 dose</li> </ul>
Stiff Person Syndrome- failed standard therapy ( i.e. diazepam, baclofen or other immunosuppressive therapy)	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days</li> </ul>
THIRD LINE INDICATIONS (require attending specialty approval)	
Clostridium difficile (severe, recurrent)- Infectious Disease attending approval	<ul style="list-style-type: none"> <li>150 mg/kg/dose x 1 dose or 400 mg/kg/dose with hypogammaglobulinemia x 1 dose</li> </ul>
Rotaviral Enterocolitis- Infectious Disease attending approval	<ul style="list-style-type: none"> <li>300 mg/kg/dose oral once</li> </ul>
Systemic Lupus Erythematosus or Vasculitic Syndromes – failed standard therapy with steroids or other immunosuppressive therapy- Rheumatology Attending Approval	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Toxic Epidermal Necrolysis/ Steven Johnson Syndrome (10% BSA involvement)- Rheumatology Attending Approval	<ul style="list-style-type: none"> <li>400 mg/kg/day x 5 days or 500 mg/kg/day x 4 days or 1 g/kg/day x 2 days</li> </ul>
Toxic Shock Syndrome or Necrotizing Fasciitis due to group A Streptococcus or Staphylococcus- Infectious Disease Attending Approval	<ul style="list-style-type: none"> <li>1 g/kg/day x 1 dose. May repeat 500 mg/kg/day x2 days</li> </ul>

